

# Ruth Lupu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5059661/publications.pdf>

Version: 2024-02-01

44  
papers

4,963  
citations

186265  
28  
h-index

254184  
43  
g-index

44  
all docs

44  
docs citations

44  
times ranked

7711  
citing authors

#	ARTICLE	IF	CITATIONS
1	Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin $\alpha 6 \beta 1$ drives endocrine resistance in breast cancer cells. <i>Aging</i> , 2022, 14, .	3.1	3
2	Depletion of CCN1/CYR61 reduces triple-negative/basal-like breast cancer aggressiveness.. <i>American Journal of Cancer Research</i> , 2022, 12, 839-851.	1.4	0
3	Fatty acid synthase: a druggable driver of breast cancer brain metastasis. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 427-444.	3.4	10
4	Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer. <i>Cancers</i> , 2021, 13, 1132.	3.7	22
5	Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. <i>Cell Death and Disease</i> , 2021, 12, 977.	6.3	33
6	Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7661.	4.1	19
7	Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 1757.	3.7	17
8	Progesterone receptor isoform-dependent cross-talk between prolactin and fatty acid synthase in breast cancer. <i>Aging</i> , 2020, 12, 24671-24692.	3.1	6
9	Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells. <i>Carcinogenesis</i> , 2018, 39, 601-613.	2.8	53
10	Fatty acid synthase is required for profibrotic TGF $\beta 2$ signaling. <i>FASEB Journal</i> , 2018, 32, 3803-3815.	0.5	52
11	A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1221-1227.	2.3	39
12	Fatty acid synthase (FASN) as a therapeutic target in breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 1001-1016.	3.4	185
13	Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer. <i>Histology and Histopathology</i> , 2017, 32, 687-698.	0.7	40
14	<i>BRCA1</i> haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells. <i>Oncotarget</i> , 2017, 8, 35019-35032.	1.8	12
15	The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells. <i>Oncoscience</i> , 2016, 3, 242-257.	2.2	19
16	Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer. <i>Oncotarget</i> , 2016, 7, 71151-71168.	1.8	40
17	Germline <i>BRCA1</i> mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based "starvation" strategies in <i>BRCA1</i> carriers. <i>Oncotarget</i> , 2016, 7, 52974-52992.	1.8	26
18	Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents. <i>Current Drug Targets</i> , 2016, 18, 147-159.	2.1	55

#	ARTICLE	IF	CITATIONS
19	Blockade of a Key Region in the Extracellular Domain Inhibits HER2 Dimerization and Signaling. Journal of the National Cancer Institute, 2015, 107, djv090.	6.3	10
20	Heregulin, a new interactor of the telosome/shelterin complex in human telomeres. Oncotarget, 2015, 6, 39408-39421.	1.8	5
21	Heregulin, a new regulator of telomere length in human cells. Oncotarget, 2015, 6, 39422-39436.	1.8	8
22	CCN1 promotes vascular endothelial growth factor secretion through $\alpha_3\beta_1$ integrin receptors in breast cancer. Journal of Cell Communication and Signaling, 2014, 8, 23-27.	3.4	11
23	Heregulin in Breast Cancer: Old Story, New Paradigm. Current Pharmaceutical Design, 2014, 20, 4874-4878.	1.9	9
24	The mitochondrial H <sup>+</sup> -ATP synthase and the lipogenic switch. Cell Cycle, 2013, 12, 207-218.	2.6	77
25	Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. Cell Cycle, 2013, 12, 3109-3124.	2.6	90
26	Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochemical and Biophysical Research Communications, 2009, 385, 454-459.	2.1	77
27	Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature Reviews Cancer, 2007, 7, 763-777.	28.4	2,355
28	Oncogenic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells. Current Opinion in Clinical Nutrition and Metabolic Care, 2006, 9, 346-357.	2.5	81
29	Targeting Fatty Acid Synthase in Breast and Endometrial Cancer: An Alternative to Selective Estrogen Receptor Modulators?. Endocrinology, 2006, 147, 4056-4066.	2.8	102
30	Pharmacological Inhibitors of Fatty Acid Synthase (FASN)-Catalyzed Endogenous Fatty Acid Biogenesis: A New Family of Anti-Cancer Agents?. Current Pharmaceutical Biotechnology, 2006, 7, 483-494.	1.6	163
31	Mediterranean Dietary Traditions for the Molecular Treatment of Human Cancer: Anti-Oncogenic Actions of the Main Olive Oils Monounsaturated Fatty Acid Oleic Acid (18:1n-9). Current Pharmaceutical Biotechnology, 2006, 7, 495-502.	1.6	88
32	A novel CYR61-triggered $\alpha_3\beta_1$ integrin loop <sup>TM</sup> regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. Oncogene, 2005, 24, 761-779.	5.9	138
33	$\alpha_3\beta_1$ integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer. Oncogene, 2005, 24, 3759-3773.	5.9	93
34	In support of fatty acid synthase (FAS) as a metabolic oncogene: Extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells. Journal of Cellular Biochemistry, 2005, 94, 1-4.	2.6	77
35	Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. International Journal of Cancer, 2005, 115, 19-35.	5.1	100
36	Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Medical Hypotheses, 2005, 64, 997-1001.	1.5	72

#	ARTICLE	IF	CITATIONS
37	Targeting Fatty Acid Synthase: Potential for Therapeutic Intervention in Her-2/neu-Overexpressing Breast Cancer. <i>Drug News and Perspectives</i> , 2005, 18, 375.	1.5	66
38	Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF- $\kappa$ B. <i>International Journal of Oncology</i> , 2004, 24, 591.	3.3	36
39	Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 10715-10720.	7.1	297
40	Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells. <i>Oncogene</i> , 2004, 23, 4945-4958.	5.9	36
41	Inhibition of Tumor-associated Fatty Acid Synthase Hyperactivity Induces Synergistic Chemosensitization of HER-2/neu-Overexpressing Human Breast Cancer Cells to Docetaxel (taxotere). <i>Breast Cancer Research and Treatment</i> , 2004, 84, 183-195.	2.5	71
42	Pharmacological inhibition of fatty acid synthase (FAS): A novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. <i>Molecular Carcinogenesis</i> , 2004, 41, 164-178.	2.7	71
43	Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells. <i>Oncology Reports</i> , 2004, 12, 411-22.	2.6	29
44	Cyr61 promotes breast tumorigenesis and cancer progression. <i>Oncogene</i> , 2002, 21, 8178-8185.	5.9	170